First Name Last Name, M - University of Colorado
S. Lindsey Davis, M.D.
University of Colorado Cancer Center
University of Colorado Denver
Mail Stop 8117
12801 East 17th Avenue Room L18-8105
Aurora, Colorado 80045
Phone: (303)724-8681 Fax: 303-724-3889
Sarah.Davis@ucdenver.edu
|Education | |
|Hematology and Oncology Fellowship, University of Colorado-Denver, Anschutz Medical Campus, Aurora, Colorado|2011-2014 |
|Internal Medicine Residency, University of Colorado-Denver, Anschutz Medical Campus, Aurora, Colorado | |
|Medical Degree, University of Missouri-Columbia School of Medicine, Columbia, Missouri |2007-2010 |
|Bachelor of Science in Microbiology (Summa Cum Laude), University of Arkansas, Fayetteville, Arkansas | |
| |2003-2007 |
| | |
| |1999-2003 |
| | |
|Current Position | |
|Assistant Professor |2014-Present |
|University of Colorado-Denver | |
|Aurora, Colorado | |
| | |
|Professional Experience | |
|Chief Fellow | |
|Division of Medical Oncology |2013-2014 |
|University of Colorado-Denver, Anschutz Medical Campus | |
|Aurora, Colorado | |
| | |
|Chief Resident | |
|Department of Internal Medicine |2010-2011 |
|University of Colorado-Denver, Anschutz Medical Campus | |
|Aurora, Colorado | |
|Certification and Licensure | |
|Diplomate, American Board of Internal Medicine |2010 |
|Colorado State Medical License (active) |2010 |
|Drug Enforcement Agency License (active) |2010 |
|Professional Memberships and Activities | |
|American Society of Clinical Oncology |2012-Present |
| | |
|Honors and Awards | |
|ASCO/AACR Methods in Clinical Cancer Research Workshop Participant |2013 |
| | |
|Committee Assignments and Administrative Services | |
|Hematology/Oncology Fellowship Program Evaluation Committee |2014-Present |
|University of Colorado Hematology-Oncology Fellowship Selection Committee |2013-Present |
|Schwartz Center Rounds Planning Committee |2013-Present |
|Hematology/Oncology Fellowship Quality Improvement Project Leader |2012-2014 |
|University of Colorado Internal Medicine Student Evaluation Committee |2010-2011 |
|University of Colorado Internal Medicine Residency Selection Committee |2009-Present |
| | |
|Educational Activities | |
|Teaching Experience | |
|Medical Student Core Curriculum Lecturer |3/2014 |
|Hematology and Oncology Grand Rounds Lecturer |3/2012, 3/2013, 1/2014 |
|Internal Medicine Grand Rounds Lecturer |11/2010 |
|Medical Student Board Review Lecturer |2011 |
|Medical Student Physical Exam Course, Small Group Leader |2010-2011 |
|Medical Student Internal Medicine Lecture Series, Coordinator and Lecturer |2010-2011 |
| | |
|Educational Course Participation | |
|Practical Application of Molecular and Cell Biology Techniques for the Clinical |2012 |
|Investigator | |
| | |
|Publications | |
|Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Want T, Albadine R, |2010 |
|Schultz L, Partin AW, Jimeno A, et al. “A pharmacodynaimc study of rapamycin in men with intermediate- to | |
|high-risk localized prostate cancer.” Clinical Cancer Research. 2010; 16(11):3057-66. | |
|Davis SL and Jimeno A. “Metastatic Colorectal Cancer: Focus on Panitumumab.” Clinical Medicine Reviews in | |
|Oncology. 2010;2:109-121. |2010 |
|Davis SL, Eckhardt SG, Messersmith WA, and Jimeno A. “The Development of Regorafenib and its Current and | |
|Potential Future Role in Cancer Therapy.” Drugs of Today. 2013; 49(2): 105-115. |2013 |
|Pitts TM, Davis SL, Eckhardt SG, and Bradshaw-Pierce EL. “Targeting Nuclear Kinases in Cancer: Development | |
|of Cell Cycle Kinase Inhibitors.” Pharmacology and Therapeutics. 2013. Advance online publication | |
|http:// dx.10.1016/j.pharmthera.2013.12.010. |2013 |
|Davis SL, Eckhardt SG, Tentler JJ, and Diamond JR. “Triple-Negative Breast Cancer: Bridging the Gap from | |
|Cancer Genomics to Predictive Biomarkers.” Therapeutic Advances in Medical Oncology. 2014. Advance online| |
|publication. DOI: 10.1177/1758834013519843. | |
|Manuscripts Accepted for Publication |2014 |
|Kessler E, Davis SL, Brittain P, Leong S, Eckhardt SG, and Lieu CH. “Targeted Therapies” American Cancer | |
|Society Textbook of Cancer | |
|Micel LN, Tentler JJ, Tan AC, Selby HM, Brunkow KL, Robertson KM, Davis SL, Pitts TM, Gangolli E,Fabrey R, | |
|O’Connell SM, Vincent P, Eckhardt SG. “Antitumor activity of the MEK inhibitor TAK-733 against melanoma | |
|cell lines and patient-derived tumor explants.” Molecular Cancer Therapeutics. | |
|Tocce K, Davis SL. “Hematologic Abnormalities” Contraception for the Medically Challenging Patient | |
|Abstracts and Presentations | |
| | |
|Posters | |
|Local/Regional Meetings | |
|Pre-Postatectomy Rapamycin in Men with Advanced Localized Prostate Cancer | |
|University of Colorado Department of Medicine Research Day |11/2008 |
| | |
|National/International Meetings | |
|A First-in-human Phase I Study of the Novel Cancer Stem Cell (CSC) Targeting Antibody | |
|OMP-52M51 (anti-Notch1) Administered Intravenously to Patients with Certain Advanced Solid Tumors |10/2013 |
|AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | |
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.